TD Cowen raised the firm’s price target on BeiGene (BGNE) to $260 from $254 and keeps a Buy rating on the shares. The firm said they have one of the best pipelines in biotech. The solid tumor pipeline progressing in breast lung and GI as well while raising Brukinsa estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene’s Financial and Market Challenges: Navigating Risks in Drug Acceptance, Competition, and Geopolitical Tensions
- BeiGene reports Q3 EPS ($1.15), consensus ($1.20)
- BeiGene, Ltd. (BGNE) Q3 Earnings Cheat Sheet
- BeiGene to share new Brukinsa data at ASH Annual Meeting
- Indaptus Therapeutics announces clinical supply agreement with BeiGene